Cagrilintide
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
Cagrilintide is a long-acting synthetic analog of the pancreatic hormone amylin, engineered for extended half-life as a dual amylin and calcitonin receptor agonist (DACRA). It is studied in metabolic research, frequently in combination with GLP-1 receptor agonists, for complementary amylin-mediated signaling.
Clinical investigation is at the phase 1/2 stage; cagrilintide is an investigational compound without an approved indication.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet. 2021;398(10317):2160-2172.
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide plus semaglutide. The Lancet. 2021;397(10286):1736-1748.
- Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry. 2021;64(15):11183-11194.
Trademarks & attribution
Cagrilintide (AM833) is an investigational compound under development by Novo Nordisk with no approved or trademarked drug product. Catalyst Research Labs is not affiliated with Novo Nordisk. Supplied as reference material only.
